Antihistamínicos:¿Sirven en melanoma?
Mayo 13, 2020
Antihistamines May Improve Survival in Patients With Malignant Melanoma
Desloratadine and loratadine use are associated with improved survival among patients with malignant melanoma, according to a study published in the journal Allergy.
"Previous studies have shown that the same antihistamines have survival benefits in breast cancer," said Håkan Olsson, Lund University, Lund, Sweden. "Now we see the same thing concerning malignant melanoma. However, more research is required to confirm the results."
The researchers examined the use of 6 antihistamines in patients diagnosed with malignant melanoma; desloratadine, cetirizine, loratadine, clemastine, ebastine, and fexofenadine.
They matched information from 3 large registers (prescribed drug register, cancer register, and cause of death register) in Sweden between 2006 and 2014 who received their first diagnosis of skin cancer (n = 24,562). Of those with a first diagnosis of skin cancer, 1,253 were antihistamine users, including desloratadine (n = 395) cetirizine (n = 324), loratadine (n = 251), or clemastine (n = 192). The other antihistamines were used by considerably fewer individuals. The follow-up of individuals was carried out until December 31, 2018.
"We observed improved survival among those who used desloratadine and to a certain extent also loratadine, particularly in those aged 65 years and older, compared with those who had not used antihistamines," said Olsson. "The use of the other antihistamines showed no significant survival effect."
"The use of desloratadine and loratadine also seemed to reduce the risk of getting a new malignant melanoma," he added. "The finding is interesting for a future drug against melanoma and may also help in advanced stages of the disease. In addition, the medicines have virtually no side effects."
The researchers are planning animal experiments and randomised studies in order to understand the mechanisms behind the effect, the appropriate dose, and optimum treatment period.
"We are collaborating with researchers in Barcelona and Stockholm.," said Olsson. "In Lund, we are underway with studies in both animal and human subjects, in which doses of antihistamines will be compared with the patients who do not take antihistamines, in order to measure the treatment effect."
Reference: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14273
SOURCE: Lund University
"Previous studies have shown that the same antihistamines have survival benefits in breast cancer," said Håkan Olsson, Lund University, Lund, Sweden. "Now we see the same thing concerning malignant melanoma. However, more research is required to confirm the results."
The researchers examined the use of 6 antihistamines in patients diagnosed with malignant melanoma; desloratadine, cetirizine, loratadine, clemastine, ebastine, and fexofenadine.
They matched information from 3 large registers (prescribed drug register, cancer register, and cause of death register) in Sweden between 2006 and 2014 who received their first diagnosis of skin cancer (n = 24,562). Of those with a first diagnosis of skin cancer, 1,253 were antihistamine users, including desloratadine (n = 395) cetirizine (n = 324), loratadine (n = 251), or clemastine (n = 192). The other antihistamines were used by considerably fewer individuals. The follow-up of individuals was carried out until December 31, 2018.
"We observed improved survival among those who used desloratadine and to a certain extent also loratadine, particularly in those aged 65 years and older, compared with those who had not used antihistamines," said Olsson. "The use of the other antihistamines showed no significant survival effect."
"The use of desloratadine and loratadine also seemed to reduce the risk of getting a new malignant melanoma," he added. "The finding is interesting for a future drug against melanoma and may also help in advanced stages of the disease. In addition, the medicines have virtually no side effects."
The researchers are planning animal experiments and randomised studies in order to understand the mechanisms behind the effect, the appropriate dose, and optimum treatment period.
"We are collaborating with researchers in Barcelona and Stockholm.," said Olsson. "In Lund, we are underway with studies in both animal and human subjects, in which doses of antihistamines will be compared with the patients who do not take antihistamines, in order to measure the treatment effect."
Reference: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14273
SOURCE: Lund University
Sent from my iPhone
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
Skin Care Physicians of Costa Rica
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
posted by dermatica at
June 05, 2020
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home